The Oncology Institute, Inc.
NASDAQ:TOIMedical - Care Facilities
-$0.07 today
- Market cap
- $512.91M
- Beta
- 0.41
- P/E (TTM)
- -121.1
- EPS (TTM)
- -$0.04
Volume 1.21M
Average 1.74M
TOI Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
The Oncology Institute, Inc.NASDAQ: TOI
Operating Margin · Q1 FY2026 · quarter ended Mar 2026
Operating margin widens to -4.4%
Operating margin was -4.4% in Q1 FY2026, up 5.1 pp from a year earlier. On a trailing-twelve-month basis it was -6.0%, up 6.9 pp year over year. Over 3 fiscal years it widened by 25.3 pp.
Context
- Operating margin widened in 3 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether operating margin reaches the consensus estimate from 3 analysts of -18.8% for the fiscal year ending Dec 2026, down from -7.2% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -4.4%+0.4 pp QoQ
- Last fiscal yearDec 2025
- -7.2%+8.1 pp YoY
- LTMMar 2026
- -6.0%+6.9 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +5.1 pp | -9.4 pp | -14.5 pp |
| 1 year | +8.1 pp | -11.6 pp | -19.7 pp |
| 3 years | +25.3 pp | -11.6 pp | -36.9 pp |
| 5 years | — | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -7.2%
- Year-over-year change
- +8.1pp
| Period | Period end | Operating Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -7.2% | +8.1pp |
| FY2024 | 2024-12-31 | -15.3% | +8.5pp |
| FY2023 | 2023-12-31 | -23.8% | +8.7pp |
| FY2022 | 2022-12-31 | -32.5% | -9.9pp |
| FY2021 | 2021-12-31 | -22.6% | — |
Operating Margin vs competitors
How TOI compares with its peers on the latest reported figures
- TOI's LTM Mar 2026 operating margin of -6.0% is the 3rd highest of the 10 companies compared; the peer median is -12.1%.
- Its year-over-year change of +6.9 pp is the 2nd highest of 10, against a peer median of -1.6 pp.
- Over three fiscal years its change of +25.3 pp compares with a peer median of +4.5 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
AUNAAuna S.A. | LTM Mar 2026 | 14.1% | -2.5 pp | +4.5 pp |
| LTM Mar 2026 | -2.1% | -0.4 pp | -10.0 pp | |
| LTM Mar 2026 | -6.0% | +6.9 pp | +25.3 pp | |
| LTM Mar 2026 | -6.8% | -1.6 pp | -2.7 pp | |
| LTM Mar 2026 | -9.6% | +5.2 pp | +31.3 pp | |
| LTM Mar 2026 | -12.1% | +5.0 pp | +8.5 pp | |
| LTM Mar 2026 | -20.5% | -16.1 pp | -3.0 pp | |
| LTM Mar 2026 | -26.9% | -2.1 pp | -0.9 pp | |
CBLLCeriBell, Inc. | LTM Mar 2026 | -68.3% | -4.3 pp | +73.4 pp |
| LTM Mar 2026 | -285.9% | +4535.6 pp | +1934.5 pp | |
| Peer median (excluding TOI) | -12.1% | -1.6 pp | +4.5 pp | |
Competitors are the stored peer set for TOI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 203M | 252.48M | 324.24M | 393.41M | 502.73M |
| Cost of Revenue | 162.16M | 200.39M | 264.67M | 339.42M | 426.29M |
| Gross Profit | 40.85M | 52.09M | 59.57M | 54M | 76.44M |
| Gross Margin | 20.1% | 20.6% | 18.4% | 13.7% | 15.2% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 0 | 0 | 0 | 0 | 105.57M |
| Operating Expenses | 86.71M | 134.04M | 136.59M | 114.12M | 112.52M |
| Depreciation & Amortization | 3.34M | 4.41M | 5.87M | 6.29M | 6.94M |
| EBITDA | (42.04M) | (67.6M) | (54.28M) | (50.88M) | (42.52M) |
| EBITDA Margin | -20.7% | -26.8% | -16.7% | -12.9% | -8.5% |
| Operating Income | (45.86M) | (81.95M) | (77.02M) | (60.12M) | (36.08M) |
| Operating Margin | -22.6% | -32.5% | -23.8% | -15.3% | -7.2% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 320K | 4.08M | 6.78M | 7.5M | 11.28M |
| Other Income / Expenses | 34.26M | 81.86M | (6.09M) | (4.55M) | (24.65M) |
| Income Before Tax | (11.6M) | (91K) | (83.1M) | (64.66M) | (60.74M) |
| Pre-Tax Margin | -5.7% | -0.0% | -25.6% | -16.4% | -12.1% |
| Income Tax Expense | (671K) | (243K) | (36K) | 0 | (131K) |
| Net Income | (10.93M) | 152K | (83.07M) | (64.66M) | (60.61M) |
| Net Margin | -5.4% | 0.1% | -25.6% | -16.4% | -12.1% |
| EPS (Basic) | (0.16) | 0.00 | (0.92) | (0.71) | (0.54) |
| EPS (Diluted) | (0.16) | (0.21) | (0.92) | (0.71) | (0.54) |
| Weighted Avg Shares | 66.23M | 72.79M | 73.75M | 75.04M | 923.89M |
| Weighted Avg Shares (Diluted) | 66.23M | 80.61M | 73.75M | 75.04M | 923.89M |
The Oncology Institute, Inc.
NASDAQ:TOI
Intrinsic Alpha fair value
Locked
Current Price
$5.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.